| Description |
DuP-721 is a broad spectrum and orally active antibacterial agent against a variety of clinically susceptible and resistant bacteria, especially M. tuberculosis[1].
|
| Related Catalog |
|
| In Vitro |
DuP-721 (1.5-4 μg/ml) inhibits equally the strains of Mycobacterium tuberculosis susceptible and resistant to conventional antituberculosis drug. And it does not show cross resistance to any of the anti-tuberculosis drugs tested[1]. DuP-721 is inactive against M. avium and M. intracellulare at 250 μg/ml. It inhibits M. gordonoe and M. fortuitum at 3.9 μg/ml and M. kansassi and M. scrofulaceum at 1.95 μg/ml and 15.6 μg/ml, respectively[1].
|
| In Vivo |
DuP-721 (oral gavage; 50-160 mg/kg) is protective against M. tuberculosis infection in mice. DuP-721 protects 100% of the infected animals at 50 mg/kg p.o. dose when administered daily for 17 days, and the same effect is observed at 160 mg/kg dose when the drug is administered only on day 11 and 12 post infection[1].
|
| References |
[1]. Affiliatio, et al. Antimycobacterial activities of oxazolidinones: a review. Infect Disord Drug Targets. 2006 Dec;6(4):343-54.
|
